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Oral Presentations 9TCD-BM1Tregs (4.5 105) compared to recipients of allogeneic
HCT only (p\ 0.05). We next examined the effects of pre-HCT
infusion of Tregs: Tregs (4 or 1.5  105) were transplanted 24 hr.
post-conditioning either 3 days pre-HCT or co-transplanted with
(day 0) donor TCD-BM. Although no difference was observed us-
ing higher Treg doses, pre-infusion - but not co-transplant of low
Treg doses was able to induce chimerism in these recipients. One
month post-HCT of TCD-BM alone, the frequency of circulating
host anti-donor tetramer1 (the immunodominant epitope H60)
CD81 cells in these recipients rejecting themarrow graft was clearly
greater compared to recipients of TCD-BM1Tregs both of which
engrafted (p\ 0.0008). However, the host anti-donor CD8 levels
were equivalent in recipients of TCD-BM alone and TCD-BM 1
Day 0 low doseTreg administration which failed to engraft. Nota-
bly, transplants using unmanipulated host Tregs failed to support
engraftment. These findings indicate that donor Tregs support chi-
merism via suppression of host anti-donor antigen-specific T cells.
Finally, the persistence of donor cells in circulation as well as in lym-
phoid tissues 3 months post-HCT indicated that long-term, stable
chimerism was established by this pre-HCT Treg regimen.
Together, our results demonstrate that donor Tregs promote
MHC-matched allogeneic marrow engraftment by suppressing
host anti-donor responses. Thus, the strategy of pre-HCTTreg in-
fusion is consistent with the notion that antigen-driven expansion of
donor anti-host reactive Treg cells can enhance hematopoietic en-
graftment. We are currently investigating host Treg expansion in
MHC-matched HCT recipients.AUTOLOGOUS TRANSPLANTS18
UTILITY OF CO-MORBIDITY ASSESSMENT IN PREDICTING TRANS-
PLANT-RELATED TOXICITY FOLLOWING AUTOLOGOUS HEMATOPOI-
ETIC TRANSPLANTATION FOR MULTIPLE MYELOMA
Labonte, L.1, Iqbal, T.2, Zaidi, M.A.1, McDiarmid, S.A.2,
Huebsch, L.B.2, Tay, J.2, Allan, D.S.1,2. 1Ottawa Health Research Pro-
gram, Ottawa, ON, Canada; 2University of Ottawa/The Ottawa Hospi-
tal, Ottawa, ON, Canada.
Background: Several randomized studies have demonstrated the
benefits and favorable toxicity following autologous hematopoietic
stem cell transplantation (AHSCT) for patients with multiple mye-
loma (MM)who are less than 55 yrs. Treatment related toxicity may
increase for older patients with co-morbidities and the benefits of
AHSCT become debatable. Decision tools for identifyingmyeloma
patients most suitable for AHSCT are needed to avoid the risk of
excess toxicity.Methods:Data regarding co-morbidities and toxic-
ity following transplant were extracted from the hospital records
and BMT database from 126 patients with MM undergoing
AHSCT between 1994 and 2006. All patients consented to the
use of medical information for research purposes. Co-morbidity
was assessed using the Charlson Co-morbidity Index (CCI), the
Haematopoietic Cell Transplantation Co-morbidity Index
(HCT-CI) and a modified Pretransplantation Assessment of Mor-
tality (mPAM). Transplant-related toxicity was assessed using
length of hospital stay (LOS) following the transplant, the total
number of organs having any toxicity according to the Seattle crite-
ria, cumulative toxicity using the scores in 8 organ systems, and non-
relapse mortality at 100 days. Results: Any co-morbidity using the
CCI (score. 0) was associated with prolonged LOS (OR 4.05, 1.76
– 9.29 for LOS greater than 18 days), more organ systems with any
toxicity (OR 2.27, 0.99 – 5.22 for at least one organ), and greater cu-
mulative organ toxicity (OR 2.2, 1.06 – 4.49 for total score $2).
Likewise, any co-morbidity using the HCT-CI (score . 0) was
also associated with longer LOS (OR 5.34, 2.24 – 12.75), increased
organ systemswith any toxicity (OR 2.5, 1.08 – 5.80) and cumulative
overall toxicity (OR 2.22, 1.08 – 4.55). A score of $24 using the
mPAM was associated with increased LOS (OR 3.03, 1.35 – 6.77)
but not with an increased number of organs with any toxicity or
with cumulative toxicity. None of the co-morbidity assessment
scales was associated with non-relapse mortality due to low inci-
dence of transplant-related death in this group (2 deaths or 1.6%).
Conclusion: Any co-morbidity identified using the CCI andHCT-CI was associated with greater toxicity following autologous
transplant for multiple myeloma. None of the scales was associated
with increasedmortality in this group. In discussingAHSCT for pa-
tients with myeloma, assessment of co-morbidities using the CCI or
HCT-CI may assist in determining the risk of toxicity.GRAFT PROCESSING19
PHARMACOLOGIC INHIBITION OF ALDEHYDE DEHYDROGENASE
(ALDH) CAUSES THE EXPANSION OF HEMATOPOIETIC STEM CELLS
(HSCs) WITH ENHANCED ENGRAFTMENT CAPACITY
Muramoto, G.G., Himburg, H., Meadows, S., Salter, A., Chao, N.J.,
Chute, J.P. Duke University, Durham, NC.
Delayed engraftment and graft failure are persistent obstacles
which limit the application of umbilical cord blood (CB) transplan-
tation in adults. We recently demonstrated that inhibition of
ALDH with diethylaminobenzaldehyde (DEAB) induced the ex-
pansion of human HSCs capable of repopulating NOD/SCID
mice (PNAS 2006 103:11707). In this study, we utilized syngeneic
CD45.1/CD45.2 mice to determine whether inhibition of ALDH
could accelerate the engraftment of transplantedHSCs in vivo. Cul-
ture of murine c-kit1sca-11lin-CD34- (34-KSL) cells with 100
mM DEAB coupled with thrombopoietin, SCF and Flt-3 ligand
(TSF) for 7 days resulted in a 22.6-fold expansion of total cells, com-
pared with 360.0-fold expansion with TSF alone (p5 0.001). How-
ever, DEAB-culture maintained a significantly higher percentage of
lin- (mean 97.1%) and KSL cells (mean 14.1%) at day 7 as com-
pared to TSF alone (42.6% and 4.7%, respectively; p\ 0.001 and
p5 0.03), indicating that inhibition of ALDH preferentially main-
tained more primitive progenitors in culture than TSF alone.
We then transplanted FACS-sorted donor CD45.11 BM
34-KSL cells or their progeny following culture with TSF alone
or TSF 1 DEAB at limiting doses into lethally irradiated
CD45.21 congenic recipients. At 4 weeks post-transplantat,
DEAB-cultured progeny showed significantly accelerated engraft-
ment in recipient mice, as compared to day 0 34-KSL cells or their
progeny following culture with TSF alone. Using Poisson statistical
analysis, the repopulating cell frequency was found to be 1 in 48.4
for the DEAB-cultured progeny (95% confidence interval: 27.3 –
86.0) as compared to 1 in 99.6; CI: 50.4 – 197.0) within the TSF-
cultured progeny. Unmanipulated BM 34-KSL cells had not yet
shown significant levels of hematopoietic engraftment at week 4
(1 in 1319.4; CI 187.2 – 9298.8). DEAB-cultured progeny also dem-
onstrated significantly higher B2201 and Thy 1.21 lymphoid con-
tribution, as compared to day 0 BM 34-KSL cells (p\ 0.001 and
p\0.001), and significantly higher level ofMac-11/Gr-11myeloid
reconstitution (p \ 0.001), compared with the progeny of TSF
alone. These data demonstrate that pharmacologic inhibition of
ALDH facilitates the differential expansion of hematopoietic pro-
genitors with enhanced early engraftment capacity. This strategy
can be particularly useful to expand human CB grafts to overcome
the delays in engraftment which currently limit this otherwise
attractive source of HSCs for adult transplantation.20
HIGHER CD341 CELL DOSES ARE ASSOCIATED WITH DECREASED RE-
LAPSE RATES FOLLOWING UNRELATED DONOR ALLOGENEIC PERIPH-
ERAL BLOOD STEM CELL TRANSPLANTATION WITH TRENDS TO
IMPROVED DISEASE-FREE SURVIVAL
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